Decisions

In a Wall Street Journal article Monday, Google’s MFWIC, Sundar Pichai, defended his decision to support the People’s Republic of China with a Google “search” engine that’s carefully compliant with PRC censorship requirements.

What interests me this time, though, is this bit:

Mr Pichai…played down the idea that the Project Maven decision was made only based on employee feedback. He said Google has also listened to experts in ethics and artificial intelligence.

Project Maven is a DoD program intended to develop artificial intelligence for American national defense purposes—including, yes, an improved ability to kill our enemies when they attack us.

Pichai’s rationalization of his decision to turn his back on our national defense doesn’t matter. Our enemies are developing AI and will use it against us. Pichai’s decision only potentiates those enemies’ relative capabilities.

Don’t be evil.  That used to be Google’s motto.  How is it evil to help our country defend itself?  How is it not evil to help our enemies, even if without AI support (other than “search” AIs)?

Now the corporate motto, handed down from parent Alphabet, is Do the right thing.  How is refusing to help our nation defend itself a right thing?  How is helping our enemies a right thing?

Sundar Pichai knows the answers to these questions full well.

Pharma and Drug Prices

The Trump administration has proposed a rule that would require companies advertising drugs to provide the list prices of those drugs in their advertising—including their television advertising.  Big Pharma is opposed, and wants instead to be left to voluntarily provide pricing information by having links in their advertising that would guide folks to a separate Web site.

I sympathize with Big Pharma on this. Government regulation already is out of hand; the Trump administration is reducing that, and this is an unnecessary addition.

There is an alternative.

The FDA could compile a list of drug list prices; region-by-region retail prices at places like Walgreens, CVS, Walmart, amazon (note that this is not an exhaustive list of retailers); and the tier within which each drug sits.  This list then could be made available on the FDA’s Web site home page above the fold.

This more central source, in addition to encouraging competition among drug companies, would encourage more competition among retailers.